Journal of Alzheimer's Disease
Published on Journal of Alzheimer's Disease (https://www.j-alz.com)

Home > PE859, A Novel Curcumin Derivative, Inhibits Amyloid-β and Tau Aggregation, and Ameliorates Cognitive Dysfunction in Senescence-Accelerated Mouse Prone 8.

TitlePE859, A Novel Curcumin Derivative, Inhibits Amyloid-β and Tau Aggregation, and Ameliorates Cognitive Dysfunction in Senescence-Accelerated Mouse Prone 8.
Publication TypeJournal Article
Year of Publication2017
AuthorsOkuda, M, Fujita, Y, Hijikuro, I, Wada, M, Uemura, T, Kobayashi, Y, Waku, T, Tanaka, N, Nishimoto, T, Izumi, Y, Kume, T, Akaike, A, Takahashi, T, Sugimoto, H
JournalJ Alzheimers Dis
Volume59
Issue1
Pagination313-328
Date Published2017
ISSN1875-8908
Abstract

Aggregation of amyloid-β (Aβ) and tau plays a crucial role in the onset and progression of Alzheimer's disease (AD). Therefore, the inhibition of Aβ and tau aggregation may represent a potential therapeutic target for AD. Herein, we designed and synthesized both Aβ and tau dual aggregation inhibitors based on the structure of curcumin and developed the novel curcumin derivative PE859. In this study, we investigated the inhibitory activity of PE859 on Aβ aggregationin vitro and the therapeutic effects of PE859 on cognitive dysfunction via dual inhibition of Aβ and tau aggregation in vivo. PE859 inhibited Aβ aggregation in vitro and protected cultured cells from Aβ-induced cytotoxicity. Furthermore, PE859 ameliorated cognitive dysfunction and reduced the amount of aggregated Aβ and tau in brains of senescence-accelerated mouse prone 8 (SAMP8). These results warrant consideration of PE859 as a candidate drug for AD.

DOI10.3233/JAD-161017
Alternate JournalJ. Alzheimers Dis.
PubMed ID28598836
E-mail Icon
Comment Icon
  • Comment
Bookmark Icon Bookmark Recommend Icon Recommend Follow Icon Follow
  • Comment
| Bookmark | Recommend | Follow

Source URL: https://www.j-alz.com/content/pe859-novel-curcumin-derivative-inhibits-amyloid-%CE%B2-and-tau-aggregation-and-ameliorates